GLP-1 Plateau: Why Weight Loss Stalls and What the Research Says

There is a version of the plateau story that circulates online — the drug “stops working,” your body “adapts,” you need to switch or escalate or take a break. Very little of that is in the research.

What is in the research is a clear, measured picture: plateaus on these drugs are near-universal, they arrive on a schedule that varies predictably with starting weight, and the drug is still doing something important once the scale goes flat. This page lays out what the studies found.

None of this is medical advice, and nothing here is a reason to change a dose or stop a medication. Those decisions belong to a healthcare provider.

About the label material on this page. Where this article describes dosing schedules, escalation, missed doses, storage or warnings, it is summarizing the FDA-approved prescribing information and Instructions for Use for Wegovy and Zepbound as published on DailyMed. Those documents are the authority, they are revised periodically, and they differ by product and by presentation (pen, prefilled syringe, single-dose vial, multi-dose vial). Follow the Instructions for Use that came with your own prescription, and take any question about your own dose, timing or supply to your prescriber or pharmacist rather than to this page.

What does “plateau” mean in the studies?

This matters more than it sounds, because the word means two different things.

In the SURMOUNT-1 and SURMOUNT-4 post hoc analyses — the only formal time-to-plateau work published for these drugs — a plateau was defined as a weight change of less than 5% across a 12-week interval, and across every subsequent 12-week interval [1].

That is a strict bar. It requires nearly three months of very little movement, followed by more of the same. It is not what most people mean when they say they have stalled.

The everyday version — the scale showing the same number for two or three weeks — is usually measurement noise. Body weight moves day to day with fluid retention, sodium intake, glycogen stores, bowel contents, the menstrual cycle and recent exercise. A single pound of glycogen carries roughly three pounds of water with it. Researchers analyze 12-week windows precisely because weekly readings are unreliable.

When does the plateau arrive?

For tirzepatide, there is a direct answer. In SURMOUNT-1, among participants who were adherent and reached at least 5% weight loss, median time to plateau was [1]:

Starting category	Median weeks to plateau
Overweight	24.3
Class I obesity	26.0
Class II obesity	36.1
Class III obesity	36.1

By week 72, 90.2%, 88.9%, 87.6% and 87.8% of participants in those four groups had plateaued [1]. In other words: almost everybody plateaus inside the first 18 months, and the heavier you start, the longer it takes.

Three factors were associated with reaching the plateau later: a higher dose (10 or 15 mg), younger age and female sex. And a longer time to plateau went with greater total weight loss [1].

For semaglutide, no equivalent formal analysis was published, but the curves say the same thing. STEP 1 reported a mean 14.9% at 68 weeks [2]. STEP 5 continued treatment to 104 weeks and reported 15.2% [3]. The entire second year added roughly nothing on average.

The same shape appears to hold much further out: in the four-year SELECT cardiovascular outcomes trial of semaglutide 2.4 mg, mean weight loss continued for roughly the first 65 weeks and was then sustained without further decline through four years. SELECT enrolled adults with established cardiovascular disease and overweight or obesity but without diabetes, so its population is not the same as the STEP trials’.

Why does it happen?

Not because the drug stops working. Because energy balance moves.

A smaller body burns less energy. Resting metabolic rate falls roughly in proportion to the tissue lost, and moving a lighter body through the day costs fewer calories. At the same time, the physiological pressure to eat more increases as fat mass falls. At some point the reduced intake the drug produces and the reduced expenditure the smaller body requires meet, and weight stabilizes.

This is not unique to GLP-1 drugs — it is the same mechanism that produces a plateau after dieting, after bariatric surgery and after any other sustained weight loss. What is different is where the plateau lands: a mean of roughly 15% below baseline on semaglutide 2.4 mg and roughly 21% on tirzepatide 15 mg, rather than the 5-7% typical of lifestyle intervention alone [2][4].

Is the drug still doing anything once you plateau?

Yes, and there is a clean experiment proving it.

STEP 4 put everyone on semaglutide for a 20-week run-in, then randomized those who reached 2.4 mg to continue or switch to placebo. From week 20 to week 68, the continuation group lost a further 7.9% of body weight. The placebo-switch group gained 6.9% [5].

SURMOUNT-4 did the same with tirzepatide over a longer lead-in. After 36 weeks averaging -20.9%, continuers lost a further 5.5% (reaching -25.3% total) while switchers regained 14.0% (ending at -9.9%). At week 88, 89.5% of continuers had kept at least 80% of their lead-in loss, against 16.6% of switchers [6].

So the flat part of the curve is the drug holding a line against a strong physiological pull in the other direction. Confusing “stopped losing” with “stopped working” is the single most common misreading of these curves.

But my curve flattened at week 10, not week 30

This is where the late-responder data becomes the most useful thing in the literature.

In SURMOUNT-1, 18% of adherent participants had lost less than 5% by week 12. They were more likely to be male and started heavier. By week 24, 70% of them had reached 5%. By week 72, 90% had. The mean time for a late responder to reach 5% was 24.8 weeks [7].

STEP 4 found the mirror image for semaglutide: being a week-20 responder predicted reaching 5% at week 68 with 96.4% accuracy, but being a week-20 non-responder had a negative predictive value of only 42.9% [8]. A slow start simply does not tell you much.

Two other things commonly get mistaken for a plateau in the first few months:

• Still climbing the dose. Escalation runs 16 weeks for semaglutide 2.4 mg, 20 weeks for semaglutide 7.2 mg and up to 20 weeks for tirzepatide [4][9]. A flat stretch mid-escalation is not the plateau the trials describe.
• Not being on the dose that produced the published numbers. In a US real-world cohort of 7,881 adults, 80.8% were on low maintenance doses, and mean one-year weight reduction was 8.7% overall — 11.9% among people who did not discontinue and 3.6% among those who stopped within three months [10].

What does the research say actually changes the plateau?

Here it is important to separate what has been tested from what gets recommended.

Continuing treatment. The best-supported answer, from STEP 4 and SURMOUNT-4 [5][6]. The plateau holds while treatment holds.

Dose. In SURMOUNT-1, higher doses produced larger results and a later plateau [1]. In the trials behind the Wegovy label — semaglutide 7.2 mg (Wegovy HD) was FDA-approved in March 2026 as a maximum dose for patients who tolerate 2.4 mg for at least four weeks — the 7.2 mg dose reached -18.8% at 72 weeks versus -15.5% for 2.4 mg, with 45.5% of the 7.2 mg group losing at least 20% against 32.3% on 2.4 mg [9]. It also came with more nausea (39% vs 35%), vomiting (22% vs 16%), fatigue (11% vs 9%) and hair loss (6% vs 3%) [9]. This is a prescriber’s decision and a trade-off, not a plateau hack.

Exercise. The strongest randomized evidence is the S-LITE trial. After an eight-week diet that produced 13.1 kg of weight loss, 195 adults were randomized for a year to supervised exercise plus placebo, liraglutide 3.0 mg, both combined, or placebo. At one year versus placebo: exercise -4.1 kg, liraglutide -6.8 kg, combination -9.5 kg. The combination cut body-fat percentage by 3.9 percentage points, roughly twice either single treatment, and was the only arm to improve HbA1c, insulin sensitivity and cardiorespiratory fitness [11]. It also preserved lean mass.

Protein and resistance training. Not tested as a plateau intervention, but repeatedly recommended in clinical-nutrition reviews for a different reason — preserving muscle during the loss phase. A 2025 American Journal of Clinical Nutrition review states plainly that increased protein alone is unlikely to preserve muscle without structured strength training, and suggests strength work at least three times weekly plus at least 150 minutes of moderate aerobic activity [12].

Switching drugs. SURMOUNT-5 found tirzepatide superior to semaglutide head to head at week 72 [13], and a 2026 meta-analysis estimated a 4.28 percentage-point advantage across 41,381 participants [14]. But no trial has tested switching after a plateau on one drug, so the effect of that specific move is unknown.

“Drug holidays” and micro-dosing. No randomized evidence supports these as plateau strategies. What is known about interrupting treatment is what SURMOUNT-4 and the STEP 1 extension showed: weight comes back.

What happens if you stop at the plateau?

A 2026 systematic review in eClinicalMedicine screened 48 studies and pooled six randomized trials (3,236 participants), modeling regain as a nonlinear recovery curve. At one year after stopping, 60% of the weight lost during treatment had been regained. Extrapolating beyond the trial data, the model projected regain plateauing at 75.3% of the weight lost — meaning some residual benefit below the original baseline, but most of it gone [15].

The STEP 1 extension gives the concrete version: 327 participants had lost 17.3% at week 68, regained 11.6 percentage points over the following year, and ended 5.6% below baseline. The share with at least 5% loss fell from 86.4% to 48.2%, and most cardiometabolic improvements reverted [16].

A 2026 post hoc analysis of SURMOUNT-4 found that 82.5% of people who stopped regained at least 25% of what they had lost within a year, and that waist circumference, systolic blood pressure, non-HDL cholesterol and HbA1c all worsened in proportion to how much came back [17].

How to think about your own flat stretch

The research supports a short list of sensible framings, none of which require doing anything drastic:

• Check the timeline against the data. If you are under 24 weeks, you are probably not at the plateau the trials describe.
• Check whether you are actually at a maintenance dose. Most real-world users are not [10].
• Use a 12-week window, not a weekly one. That is what the researchers do.
• Measure something besides weight. In the SURMOUNT-1 DXA substudy (n=160), waist circumference fell 18.1 cm on tirzepatide against 3.4 cm on placebo, and body composition kept improving even while the scale slowed [18].
• Bring it to your prescriber rather than solving it alone. Dose, timing, other medications, thyroid function, sleep and alcohol are all things a clinician can look at and you cannot.

The plateau is not the failure state of this treatment. It is the expected end of the loss phase and the start of the maintenance phase — and the trials are unambiguous that maintenance is where the benefit either holds or unwinds.

Sources

1. Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity 2025. https://doi.org/10.1111/cob.12734
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
3. Garvey WT et al. Two-year effects of semaglutide: the STEP 5 trial. Nature Medicine 2022. https://www.nature.com/articles/s41591-022-02026-4
4. Zepbound (tirzepatide) prescribing information via DailyMed, revised August 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
5. Rubino D et al. STEP 4. JAMA 2021. https://jamanetwork.com/journals/jama/fullarticle/2777886
6. Aronne LJ et al. SURMOUNT-4. JAMA 2023. https://pubmed.ncbi.nlm.nih.gov/38078870/
7. Ard JD et al. Weight reduction over time by early weight loss response: SURMOUNT-1 post hoc. Diabetes Obes Metab 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12326891/
8. Mosenzon O et al. STEP 4 post hoc analysis of early response. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8265765/
9. Wegovy (semaglutide) prescribing information via DailyMed, June 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
10. Gasoyan H et al. Changes in weight and glycemic control by discontinuation status. Obesity 2025. https://doi.org/10.1002/oby.24331
11. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. NEJM 2021. https://www.nejm.org/doi/full/10.1056/nejmoa2028198
12. Nutritional priorities to support GLP-1 therapy for obesity. Am J Clin Nutr 2025. https://ajcn.nutrition.org/article/S0002-9165(25)00240-0/fulltext
13. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. NEJM 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
14. Comparative Efficacy of Tirzepatide Versus Semaglutide: Meta-Analysis. Clinical Obesity 2026. https://doi.org/10.1111/cob.70111
15. Moiz A et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine 2026. https://doi.org/10.1016/j.eclinm.2026.103796
16. Wilding JPH et al. STEP 1 trial extension. Diabetes Obes Metab 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/
17. Horn DB et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity. JAMA Internal Medicine 2026;186(2):157. https://doi.org/10.1001/jamainternmed.2025.6112
18. Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab 2025;27(6):3230-3241. https://doi.org/10.1111/dom.16275